Permission to publish

Permission to publish and disclosure of results

This policy governs the publication, presentation, disclosure, or other communication of information relating to 3Dresyns Products, Services, Confidential Information, collaborative projects, and proprietary technology.

Its purpose is to protect legitimate Confidential Information, trade secrets, intellectual property, unpublished technical information, and contractual confidentiality obligations without claiming ownership of independently generated research or testing results merely because they relate to a 3Dresyns Product.

This policy concerns the disclosure of Company Confidential Information and of the Recipient's own independently generated results. It does not apply to the reuse, redistribution, translation, or adaptation of documents that the Company has itself published as open access works under an open licence, which are governed exclusively by the terms of that licence and by the Company's Open access publications policy. No pre-publication review, notice, or authorization is required in order to reuse such a document on the terms of its licence.

Independent testing and research results

Purchase or legitimate use of a 3Dresyns Product does not, by itself, transfer to the Company ownership of independently generated research data, testing results, scientific observations, conclusions, or other intellectual output created by a Buyer or third party.

Subject to the restrictions concerning Confidential Information, trade secrets, reverse engineering, intellectual property, trademarks, and other applicable contractual obligations described below, independently generated testing or research results do not require prior Company approval solely because they concern or identify a 3Dresyns Product.

Nothing in this policy requires a researcher, customer, or other Recipient to obtain Company approval merely because independently obtained results are favorable, unfavorable, comparative, critical, or otherwise relevant to a 3Dresyns Product.

Confidential Information and trade secrets

The Recipient shall not publish, present, disclose, submit, or otherwise communicate Company Confidential Information, protected trade secrets, proprietary compositional information, non-public formulation information, confidential Curing Rate Tables (CRTs), non-public calibration information, unpublished technical data supplied by the Company, or other information subject to a valid confidentiality obligation without the authorization required by the applicable Legal Terms, NDA, or other written agreement.

This restriction applies regardless of whether disclosure is made through:

• scientific papers or preprints;
• technical reports or white papers;
• conference presentations, abstracts, posters, or proceedings;
• theses or dissertations;
• datasets or supplementary information;
• websites, social media, forums, or online publications;
• marketing or commercial materials;
• press releases;
• oral presentations or demonstrations; or
• any other public or third-party disclosure.

Information obtained through prohibited reverse engineering

Information obtained through activity that breaches the Company's applicable contractual restrictions on reverse engineering, compositional analysis, de-formulation, or unauthorized acquisition of Confidential Information may not be published or disclosed in circumvention of those restrictions.

This provision must be read together with the Company's Prohibition against reverse engineering and penalties and Confidentiality policies.

Collaborative, confidential, and Company-supported projects

Where research, testing, development, validation, customization, technology transfer, or another project involves Company Confidential Information, unpublished Company data, proprietary technology, or information supplied under an NDA or another written confidentiality arrangement, a pre-publication review may be required.

Where such a review obligation applies, the Recipient shall provide the Company with the complete manuscript, presentation, report, abstract, dataset, or other material intended for disclosure (the “Publication”) at least thirty (30) calendar days before the proposed submission or public disclosure.

The Publication must be sent to info@3Dresyns.com, unless another contact or procedure has been agreed in writing for the relevant project.

Scope of Company pre-publication review

Where a pre-publication review applies, the Company's review is intended to identify:

• Company Confidential Information or trade secrets that must not be publicly disclosed;
• information protected by an applicable NDA or other confidentiality obligation;
• proprietary compositional or technical information disclosed beyond the authorized purpose;
• Company intellectual property requiring protection before public disclosure;
• unauthorized use of Company-owned text, images, technical documentation, trademarks, logos, or other protected content;
• incorrect attribution of statements, data, specifications, or conclusions to the Company; and
• material factual inaccuracies concerning information originally supplied by the Company.

The Company may provide technical comments concerning methodology, interpretation, or presentation. Such comments are advisory unless the relevant matter involves Confidential Information, a contractual obligation, Company-owned intellectual property, an agreed collaborative-project requirement, or another matter for which the Company has a valid contractual or legal right to require correction or removal.

The Company shall not withhold permission under a contractual pre-publication review solely because independently generated results are unfavorable to the Company or its Products.

Company response

Where this policy requires pre-publication review, the Company should communicate any objection relating to Confidential Information, trade secrets, Company intellectual property, contractual restrictions, or inaccurate attribution within the applicable thirty (30) calendar day review period.

Where the Company identifies protected Confidential Information or another disclosure that would breach an applicable contractual obligation, the Recipient must remove, redact, or otherwise appropriately protect that information before publication.

The parties should cooperate in good faith to resolve legitimate confidentiality or intellectual-property concerns without unnecessarily preventing publication of independently generated results.

No response within the review period

If a pre-publication review is contractually required and the Company does not provide comments within thirty (30) calendar days after confirmed receipt of the complete Publication, the Recipient may proceed with the proposed publication subject to the continuing obligations described in this policy.

For the avoidance of doubt, expiry of the review period does not authorize publication of information that the Recipient knows, or reasonably should know, constitutes Company Confidential Information, a protected trade secret, information subject to an NDA, or material whose disclosure is otherwise prohibited by an applicable written agreement or mandatory law.

Specific research and development agreements

Where the parties have entered into a separate NDA, research agreement, development agreement, validation agreement, technology-transfer agreement, funded-project agreement, or other individually negotiated written contract containing publication provisions, the publication provisions of that agreement shall prevail for the project or information specifically governed by it.

Such agreements may establish project-specific review, confidentiality, intellectual-property, authorship, attribution, or publication procedures different from this general policy.

Use of 3Dresyns name and trademarks

Accurate identification of a 3Dresyns Product used in legitimate research or testing does not, by itself, imply Company sponsorship, endorsement, collaboration, or approval of the research or its conclusions.

The Company's trademarks, logos, brand assets, photographs, marketing materials, and other protected content must not be used in a manner that falsely implies sponsorship, endorsement, certification, partnership, or approval by 3Dresyns.

Identification of the Company as author and publisher for the purpose of complying with the attribution conditions of an open licence is likewise a truthful factual reference and does not, by itself, imply sponsorship, endorsement, certification, or partnership.

Use of Company logos and other brand assets is subject to the Company's Use of logo policy.

Attribution and statements concerning the Company

A Publication must not attribute to the Company statements, conclusions, approvals, certifications, test results, guarantees, or positions that the Company has not actually made or accepted.

Where Company-supplied data or technical information is reproduced or referenced, its source and status should be represented accurately.

Nothing in this policy prohibits truthful criticism, genuine complaints, independently reached scientific conclusions, or unfavorable results merely because they concern the Company or a 3Dresyns Product.

Mandatory and legally protected disclosures

Nothing in this policy prohibits a disclosure that cannot lawfully be restricted, including disclosures required by applicable law, a competent authority, regulatory obligations, judicial proceedings, the exercise or defence of legal rights, or other legally protected disclosures.

Where legally permissible, a Recipient required to disclose Company Confidential Information should notify the Company in advance and disclose only the information legally required so that appropriate confidentiality measures may be considered.

Relationship with other Legal Terms

This policy must be read together with the Company's:

• Open access publications;
• Confidentiality policy;
• Prohibition against reverse engineering and penalties;
• Ownership of contents;
• Use of logo;
• Terms & Conditions; and
• Legal Terms.

Mandatory rights

Nothing in this policy excludes, restricts, or modifies any right to publish, communicate, disclose, report, criticize, or exercise a legal remedy that cannot lawfully be excluded or restricted.